Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 0.65 |
| ▸ | CRBN | Q96SW2 | 18/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.65 |
| ▸ | IL1B | P01584 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070618 | 1.00 | DDB1 (0.65) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22636788 | 1.00 | DDB1 (0.65) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22443118 | 1.00 | DDB1 (0.65) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL20919942 | 0.96 | DDB1 (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26317539 | 0.94 | DDB1 (0.68) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21070320 | 0.93 | CRBN (0.62) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21070108 | 0.92 | DDB1 (0.58) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21227696 | 0.91 | DDB1 (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19481914 | 0.91 | DDB1 (0.55) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL28507823 | 0.90 | CRBN (0.61) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | claimed |
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| CN-109415336-B | MDM2 protein degradation agent | 密执安大学评议会 | 2023-08-29 | — | — | CN | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3440066-B1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022148459-A1 | CLASS OF NOVEL SMAD3 PROTEIN DEGRADERS AND APPLICATION THEREOF | 和径医药科技（上海）有限公司 | 2022-07-14 | — | — | WO | disclosed |
| CN-113788818-A | MDM2 protein degrading agent | 密执安大学评议会 | 2021-12-14 | — | — | CN | disclosed |
| US-11192898-B2 | MDM2 protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3440066-A1 | MDM2 PROTEIN DEGRADERS | The Regents of The University of Michigan (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3440082-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | The Regents of The University of Michigan (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017180417-A1 | BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017176957-A1 | MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176958-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176957-A1 | MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176958-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | DDB1 161/4885CRBN 45/4885IKZF3 617/4885 |
| US-11192898-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | DDB1 68/4885CRBN 605/4885IKZF3 555/4885 |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | DDB1 313/4885CRBN 151/4885IKZF3 231/4885 |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | MDM2, TP53, TP53BP1 | DDB1 68/4885CRBN 605/4885IKZF3 555/4885 |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | DDB1 1141/4885CRBN 527/4885IKZF3 3509/4885 |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | DDB1 313/4885CRBN 151/4885IKZF3 231/4885 |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | MDM2, TP53, TP53BP1 | DDB1 68/4885CRBN 605/4885IKZF3 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.